Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRB | P28702 | 9/20 | 0.59 |
| ▸ | RXRA | P19793 | 9/20 | 0.59 |
| ▸ | RXRG | P48443 | 6/20 | 0.59 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5656913 | 0.82 | LMNA (0.45) | RXRBRXRARXRGLMNASMN1; SMN2 | |
| SCHEMBL3408719 | 0.82 | RXRB (0.55) | RXRBRXRARXRGLMNASMN1; SMN2 | |
| SCHEMBL8638947 | 0.81 | RXRB (0.54) | RXRBRXRARXRGLMNASMN1; SMN2 | |
| SCHEMBL11097326 | 0.80 | CXCL8 (0.79) | CXCL8CHRM1 | |
| SCHEMBL5657571 | 0.80 | RXRA (0.53) | RXRBRXRARXRGMRGPRX4IDO1 | |
| SCHEMBL5658539 | 0.80 | LMNA (0.42) | RXRBRXRARXRGLMNASMN1; SMN2 | |
| SCHEMBL28739318 | 0.79 | RXRB (0.55) | RXRBRXRARXRGLMNASMN1; SMN2 | |
| SCHEMBL31312989 | 0.78 | BCL2L1 (0.54) | RXRBRXRARXRGSMN1; SMN2MRGPRX4 | |
| SCHEMBL5660348 | 0.77 | ALOX15 (0.54) | RXRBRXRARXRGCXCL8SMN1; SMN2 | |
| SCHEMBL5660017 | 0.76 | SMN1; SMN2 (0.40) | RXRBRXRARXRGLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262309-B2 | 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | GLAXOSMITH KLINE ISTRAZIVOCKI CENTAR ZAGREB, D.O.O. (HR) | 2007-08-28 | — | — | US | disclosed |
| EP-1492795-B1 | 1- OR 3-THIA-BENZONAPHTHOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | PLIVA ISTRAZIVACKI INST D O O (HR) | 2005-11-16 | — | — | EP | disclosed |
| US-20050130964-A1 | 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130964-A1 | 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | TNF, IL1A, IL1B | RXRB 3752/4885RXRA 3077/4885RXRG 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.